Takashi Sasayama

Prof. Dr. Takashi Sasayama


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Cell
Verified
Journal Article
Closed access
THToru Hirota
Toru Hirota
NKNaoko Kunitoku
Naoko Kunitoku
TSTakashi Sasayama
Takashi Sasayama
TMTomotoshi Marumoto
Tomotoshi Marumoto
DZDongwei Zhang
Dongwei Zhang
HSHideyuki Saya
Hideyuki Saya

19 November 2001 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
IOIsamu Okamoto
Isamu Okamoto
YKYoshiaki Kawano
Yoshiaki Kawano
DMDaizo Murakami
Daizo Murakami
TSTakashi Sasayama
Takashi Sasayama
NANorie Araki
Norie Araki
HSHideyuki Saya
Hideyuki Saya
CD44 is a widely distributed cell surface adhesion molecule and is implicated in diverse biological processes. However, the nature of intracellular signaling triggered by CD44 remains to be elucidated. Here, we show that CD44 undergoes sequential proteolytic cleavage in the ectodomain and intracellular domain, resulting in the release of a CD44 intracellular domain (ICD) fragment. Consequently, CD44ICD acts as a signal transduction molecule, where it translocates to the nucleus and activates transcription mediated through the 12-O-tetradecanoylphorbol 13-acetate–responsive element, which is found in numerous genes involved in diverse cellular processes. Expression of an uncleavable CD44 mutant as well as metalloprotease inhibitor treatment blocks CD44-mediated transcriptional activation. In search of the underlying mechanism, we have found that CD44ICD potentiates transactivation mediated by the transcriptional coactivator CBP/p300. Furthermore, we show that cells expressing CD44ICD produce high levels of CD44 messenger RNA, suggesting that the CD44 gene is one of the potential targets for transcriptional activation by CD44ICD. These observations establish a novel CD44 signaling pathway and shed new light on the functional link between proteolytic processing of an adhesion molecule at the cell surface and transcriptional activation in the nucleus.

14 July 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TSTakashi Sasayama
Takashi Sasayama
MNMasamitsu Nishihara
Masamitsu Nishihara
TKTakeshi Kondoh
Takeshi Kondoh
KHKohkichi Hosoda
Kohkichi Hosoda
EKEiji Kohmura
Eiji Kohmura
MicroRNAs (miRNAs) are effective post‐transcriptional regulators of gene expression and are important in many biological processes. Although the oncogenic and tumor suppressive functions of several miRNAs have been characterized, the role of miRNAs in mediating tumor invasion and migration remains largely unexplored. Recently, miR‐10b was identified as an miRNA highly expressed in metastatic breast cancer, promoting cell migration and invasion. Here, we performed real‐time reverse transcriptase polymerase chain reaction (RT‐PCR) assays on 43 glioma samples (17 glioblastoma, 6 anaplastic astrocytoma, 10 low‐grade astrocytoma, 6 oligodendroglioma and 4 ependymoma) and 6 glioma cell lines. We found that miR‐10b expression was upregulated in all glioma samples compared to non‐neoplastic brain tissues. The expression levels of miR‐10b were associated with higher grade glioma. In addition, mRNA expressions of RhoC and urokinase‐type plasminogen activator receptor (uPAR), which were thought to be regulated by miR‐10b via HOXD10, were statistically significantly correlated with the expression of miR‐10b (p < 0.001, p = 0.001, respectively). Also, protein expression levels of RhoC and uPAR were associated with expression levels of miR‐10b (p = 0.009, p = 0.014, respectively). Finally, multifocal lesions on enhanced MRI of 7 malignant gliomas were associated with higher expression levels of miR‐10b (p = 0.02). Our data indicated that miR‐10b might play some role in the invasion of glioma cells. © 2009 UICC

1 December 2003 in Developmental Cell
Verified
Journal Article
Closed access
NKNaoko Kunitoku
Naoko Kunitoku
TSTakashi Sasayama
Takashi Sasayama
TMTomotoshi Marumoto
Tomotoshi Marumoto
DZDongwei Zhang
Dongwei Zhang
SHShinobu Honda
Shinobu Honda
THToru Hirota
Toru Hirota

23 March 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KTKazuhiro Tanaka
Kazuhiro Tanaka
TSTakashi Sasayama
Takashi Sasayama
YIYasuhiro Irino
Yasuhiro Irino
KTKumi Takata
Kumi Takata
HNHiroaki Nagashima
Hiroaki Nagashima
EKEiji Kohmura
Eiji Kohmura
The mechanistic target of rapamycin (mTOR) is hyperactivated in many types of cancer, rendering it a compelling drug target; however, the impact of mTOR inhibition on metabolic reprogramming in cancer is incompletely understood. Here, by integrating metabolic and functional studies in glioblastoma multiforme (GBM) cell lines, preclinical models, and clinical samples, we demonstrate that the compensatory upregulation of glutamine metabolism promotes resistance to mTOR kinase inhibitors. Metabolomic studies in GBM cells revealed that glutaminase (GLS) and glutamate levels are elevated following mTOR kinase inhibitor treatment. Moreover, these mTOR inhibitor–dependent metabolic alterations were confirmed in a GBM xenograft model. Expression of GLS following mTOR inhibitor treatment promoted GBM survival in an α-ketoglutarate–dependent (αKG-dependent) manner. Combined genetic and/or pharmacological inhibition of mTOR kinase and GLS resulted in massive synergistic tumor cell death and growth inhibition in tumor-bearing mice. These results highlight a critical role for compensatory glutamine metabolism in promoting mTOR inhibitor resistance and suggest that rational combination therapy has the potential to suppress resistance.

25 June 2015 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
PDF file
TNT. Nakamura
T. Nakamura
KTK. Tateishi
K. Tateishi
TNT. Niwa
T. Niwa
YMY. Matsushita
Y. Matsushita
KTK. Tamura
K. Tamura
KIKoichi Ichimura
Koichi Ichimura
Aims: Primary central nervous system lymphoma (PCNSL) manifest aggressive clinical behaviour and have poor prognosis. Although constitutive activation of the nuclear factor‐κB (NF‐κB) pathway has been documented, knowledge about the genetic alterations leading to the impairment of the NF‐κB pathway in PCNSLs is still limited. This study was aimed to unravel the underlying genetic profiles of PCNSL.Methods: We conducted the systematic sequencing of 21 genes relevant to the NF‐κB signalling network for 71 PCNSLs as well as the pyrosequencing of CD79B and MYD88 mutation hotspots in a further 35 PCNSLs and 46 glioblastomas (GBMs) for validation.Results: The results showed that 68 out of 71 PCNSLs had mutations in the NF‐κB gene network, most commonly affecting CD79B (83%), MYD88 (76%), TBL1XR1 (23%), PRDM1 (20%) and CREBBP1 (20%). These mutations, particularly CD79B and MYD88, frequently coincided within each tumour in various combinations, simultaneously affecting diverse pathways within the network. No GBMs had hotspot mutation of CD79B Y196 and MYD88 L265.Conclusions: The prevalence of CD79B and MYD88 mutations in PCNSLs was considerably higher than reported in systemic diffuse large B‐cell lymphomas. This observation could reflect the paucity of antigen stimuli from the immune system in the central nervous system (CNS) and the necessity to substitute them by the constitutive activation of CD79B and MYD88 that would initiate the signalling cascades. These hotspot mutations may serve as a genetic hallmark for PCNSL serving as a genetic marker for diagnose and potential targets for molecular therapy.